TREVI THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.83 USD | +2.17% |
|
+3.66% | +111.19% |
| May. 07 | Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
| May. 07 | Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 66.88 | 44.48 | 20.22 | 115.7 | 85.57 | 195.1 | - | - |
| Enterprise Value (EV) 1 | 66.88 | 44.48 | 20.22 | 4.292 | 85.57 | 88.31 | 6.805 | 112 |
| P/E ratio | -1.64 x | -1.34 x | -0.52 x | -4.29 x | -4.62 x | -6.48 x | -6.02 x | -4.05 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 165 x |
| EV / Revenue | - | - | - | - | - | - | - | 94.9 x |
| EV / EBITDA | -2.51 x | -1.37 x | -0.62 x | -0.14 x | -2.53 x | -1.8 x | -0.11 x | -1.37 x |
| EV / FCF | -2.89 x | -1.53 x | - | - | - | -1.89 x | -0.12 x | -1.76 x |
| FCF Yield | -34.5% | -65.3% | - | - | - | -53% | -843% | -56.8% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,835 | 18,381 | 25,847 | 59,923 | 63,858 | 70,435 | - | - |
| Reference price 2 | 3.750 | 2.420 | 0.7822 | 1.930 | 1.340 | 2.770 | 2.770 | 2.770 |
| Announcement Date | 3/16/20 | 3/25/21 | 3/17/22 | 3/16/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 1.18 |
| EBITDA 1 | -26.61 | -32.44 | -32.43 | -29.89 | -33.8 | -49.08 | -61.42 | -81.84 |
| EBIT 1 | -26.64 | -32.49 | -32.48 | -29.91 | -33.92 | -45.57 | -50.3 | -66.01 |
| Operating Margin | - | - | - | - | - | - | - | -5,594.05% |
| Earnings before Tax (EBT) 1 | -26.07 | -32.78 | -33.96 | -29.19 | -29.1 | -42.43 | -42.85 | -61.15 |
| Net income 1 | -26.75 | -32.76 | -33.94 | -29.15 | -29.06 | -43.4 | -53.5 | -79.1 |
| Net margin | - | - | - | - | - | - | - | -6,703.39% |
| EPS 2 | -2.280 | -1.810 | -1.490 | -0.4500 | -0.2900 | -0.4275 | -0.4600 | -0.6833 |
| Free Cash Flow 1 | -23.1 | -29.03 | - | - | - | -46.8 | -57.4 | -63.6 |
| FCF margin | - | - | - | - | - | - | - | -5,389.83% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/25/21 | 3/17/22 | 3/16/23 | 3/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -8.26 | -7.014 | -7.812 | -8.396 | -6.614 | -7.544 | -8.382 | -9.01 | -8.898 | -11.91 | -12.18 | -12.3 | -12.69 |
| EBIT 1 | -8.272 | -7.025 | -7.82 | -8.405 | -6.657 | -7.563 | -8.382 | -9.045 | -8.933 | -11.91 | -11.22 | -11.52 | -10.95 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.526 | -7.334 | -8.056 | -8.273 | -5.525 | -6.408 | -7.175 | -7.711 | -7.803 | -10.91 | -10.47 | -10.83 | -9.867 |
| Net income 1 | -8.521 | -7.329 | -8.052 | -8.266 | -5.505 | -6.401 | -7.145 | -7.698 | -7.821 | -10.9 | -10.65 | -11.12 | -10.58 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2800 | -0.2400 | -0.1400 | -0.1200 | -0.0600 | -0.0600 | -0.0700 | -0.0800 | -0.0800 | -0.1100 | -0.1075 | -0.1075 | -0.1000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/17/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/16/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/20/24 | 5/7/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 111 | - | 107 | 188 | 83.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -23.1 | -29 | - | - | - | -46.8 | -57.4 | -63.6 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.01 | 0.03 | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/25/21 | 3/17/22 | 3/16/23 | 3/20/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.77
USD
Average target price
7.4
USD
Spread / Average Target
+167.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +111.19% | 195M | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
- Stock Market
- Equities
- TRVI Stock
- Financials Trevi Therapeutics, Inc.
